OBiO viral vector CDMO platform launched in Zhangjiang

Updated:2019-03-11 (


The launching ceremony of the viral vector CDMO platform of OBiO Technology on Mar 5. [Photo/WeChat account: zj-toutiao]

OBiO Technology (Shanghai) Corp Ltd launched a CDMO (contract development and manufacturing organization) production platform in Shanghai's Zhangjiang National Innovation Demonstration Zone jointly with GE Healthcare on Mar 5.

The platform is the first GMP (good manufacturing practice) standard production platform in China to adopt one-off production technology and use multiple recombinant viruses for clinical and commercial treatment of gene therapy and cell therapy.

To date, the platform has cooperated with many gene therapy and cell therapy drug companies to carry out CDMO projects, including adenoviruses, poxviruses and other allied products.

With this platform, OBiO is able to provide one-stop service from pilot testing and clinical application to GMP production, meeting the needs of domestic and foreign gene therapy, CAR-T and other cell therapy drug customers at different stages of development.

Ding Jian, an academician of the Chinese Academy of Engineering, believes that the platform is of great significance in promoting the development of gene therapy in China.

According to OBiO, the platform can produce drug carriers for 150 patients at a time and serve a total of 2,000 patients a year.


OBiO Technology (Shanghai) Corp Ltd is a leading high-tech enterprise in China. It focuses on viral vector packaging service for basic life science research, gene and cell therapy drug development and clinical preparation. [Photo/WeChat account: zj-toutiao]